13th International workshop on Clinical Pharmacology of HIV Therapy, 16–18 April 2012, Barcelona
This important annual workshop always includes studies that are not presented at other meetings and it is appreciated that the organisers have made both the abstract book and many of the presentations available to download in PDF format.
Reports on drug interactions are selected, and in some cases summarised, from a full report produced by the pharmacology group at Liverpool University (www.druginteractions.org).
The full Liverpool report is available online and in PDF format.
Studies in this HTB include:
- Studies on pipeline ARVs: Quad, evitegravir/cobicistat, cobisistat, GSK1265744, BMS986001 dolutegravir, GSK-1265744, long acting formulations (monthly injections): rilpivirine-LA, raltegravir and patient views.
- Washout pharmacokinetics of transplacental raltegravir in neonates
- Interactions between malaria drugs and etravirine or darunavir/r
- Antimalarial amodiaquine and nevirapine
- Atazanavir/ritonavir plus raltegravir
- Atazanavir/ritonavir and voriconazole not to be coadministered
- Milk thistle (silymarin) and darunavir/ritonavir
- Echinacea and etravirine
- Warfarin and ARVs: impact of African American race and ritonavir
Abbreviations used in these reports include:
Cmax = Maximum concentration; Cmin = minimum concentration; AUC = Area Under the Curve; GMR = Geometric Mean Ratio; IC90/50 = Inhibitory Concentration needed to reduce viral production by 90/50% in vitro.